Myriad
Myriad Genetics Reports 7 Percent Rise in Q4 Revenues, Appoints New CEO
Myriad's full-year 2024 revenues grew 11 percent year over year driven by growth across most of its test offerings, and the company said that current COO Sam Raha will replace CEO Paul Diaz.
Myriad Genetics Exclusively Licenses Pathomiq Prostate Cancer Image Analysis Technology in US
The deal allows Myriad to combine Pathomiq's image-based patient stratification and treatment response technology with the Prolaris assay.
Craig-Hallum Initiates Coverage of Myriad Genetics With a Buy Rating
Craig-Hallum expects stable Prolaris revenues and sees opportunities for significant growth in the hereditary cancer and prenatal testing markets.
In Brief This Week: Tempus AI, Myriad Genetics, 23andMe, DNAnexus, Dovetail Genomics
News items for the week of Feb. 3, 2025.
Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform
Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.
Dec 13, 2024